MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Danaher Corp

Fechado

SetorSaúde

197.94 -3.52

Visão Geral

Variação de preço das ações

24h

Atual

Mín

197.71

Máximo

204.96

Indicadores-chave

By Trading Economics

Rendimento

268M

1.1B

Vendas

738M

6.5B

P/E

Médio do Setor

38.752

63.778

EPS

2.14

Rendimento de Dividendos

0.62

Margem de lucro

16.611

Funcionários

61,000

EBITDA

-230M

1.4B

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+28.05% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

0.62%

2.39%

Próximos Ganhos

22 de abr. de 2025

Próxima data de dividendos

25 de abr. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-16B

147B

Abertura anterior

201.46

Fecho anterior

197.94

Sentimento de Notícias

By Acuity

33%

67%

106 / 386 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

Danaher Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

5 de fev. de 2025, 12:54 UTC

Ganhos

Johnson Controls Names Weidemanis CEO, Logs 1Q Income Growth

29 de jan. de 2025, 11:44 UTC

Ganhos

Danaher 4Q Revenue Rises on Gains in Life Sciences, Biotech

22 de out. de 2024, 10:35 UTC

Ganhos

Danaher 3Q EPS, Sales Top Views on Strong Cepheid Test Demand

23 de jul. de 2024, 10:55 UTC

Ganhos

Danaher Expects 3Q Core Sales Drop, Backs 2024 Guidance

29 de jan. de 2025, 15:25 UTC

Conversa de Mercado
Ganhos

Danaher's 2025 Sales Guidance Disappoints -- Market Talk

29 de jan. de 2025, 13:56 UTC

Principais Notícias
Ganhos

Danaher Had an Unusual Quarter. The Stock Is Down. -- Barrons.com

29 de jan. de 2025, 11:08 UTC

Ganhos

Danaher Sees 2025 Bioprocessing Core Revenue Growth 6%-7% >DHR

29 de jan. de 2025, 11:07 UTC

Ganhos

Danaher Sees 2025 Adjusted Operating Profit Margin About 28.5% >DHR

29 de jan. de 2025, 11:07 UTC

Ganhos

Danaher: Expect to Return to Growth, Build Back to Normal Market Conditions in 2025 >DHR

29 de jan. de 2025, 11:02 UTC

Ganhos

Danaher Sees 2025 Adjusted Core Revenue Up About 3% >DHR

29 de jan. de 2025, 11:01 UTC

Ganhos

Danaher Sees 1Q Adjusted Core Revenue Down Low-Single Digits >DHR

29 de jan. de 2025, 11:01 UTC

Ganhos

Danaher 4Q Operating Cash Flow $2B, Free Cash Flow $1.5B >DHR

29 de jan. de 2025, 11:00 UTC

Ganhos

Danaher 4Q Adjusted Core Revenue Rose 1% >DHR

29 de jan. de 2025, 11:00 UTC

Ganhos

Danaher 4Q Cont Ops EPS $1.49 >DHR

29 de jan. de 2025, 11:00 UTC

Ganhos

Danaher 4Q Net $1.09B >DHR

29 de jan. de 2025, 11:00 UTC

Ganhos

Danaher 4Q EPS $1.49 >DHR

29 de jan. de 2025, 11:00 UTC

Ganhos

Danaher 4Q Adj EPS $2.14 >DHR

29 de jan. de 2025, 11:00 UTC

Ganhos

Danaher 4Q Sales $6.5B >DHR

22 de out. de 2024, 10:02 UTC

Ganhos

Danaher 3Q Adjusted Core Revenue Rose 0.5% >DHR

22 de out. de 2024, 10:02 UTC

Ganhos

Danaher Still Sees 2024 Adjusted Core Revenue Down Low-Single Digits >DHR

22 de out. de 2024, 10:01 UTC

Ganhos

Danaher Sees 4Q Adjusted Core Revenue Down Low-Single Digits >DHR

22 de out. de 2024, 10:00 UTC

Ganhos

Danaher 3Q Operating Cash Flow $1.5B, Adjusted Free Cash Flow $1.2B >DHR

22 de out. de 2024, 10:00 UTC

Ganhos

Danaher 3Q Sales $5.8B >DHR

22 de out. de 2024, 10:00 UTC

Ganhos

Danaher 3Q EPS $1.12 >DHR

22 de out. de 2024, 10:00 UTC

Ganhos

Danaher 3Q Adj EPS $1.71 >DHR

22 de out. de 2024, 10:00 UTC

Ganhos

Danaher 3Q Net $818M >DHR

22 de out. de 2024, 10:00 UTC

Ganhos

Danaher 3Q Cont Ops EPS $1.12 >DHR

23 de jul. de 2024, 12:39 UTC

Principais Notícias
Ganhos

Danaher Stock Surges. More Than Earnings Are Driving It Higher. -- Barrons.com

23 de jul. de 2024, 10:05 UTC

Ganhos

Danaher 2Q Adjusted Core Revenue Fell 3.5% >DHR

23 de jul. de 2024, 10:05 UTC

Ganhos

Danaher Sees 2024 Adjusted Core Revenue Down Low-Single Digits >DHR

Comparação entre Pares

Variação de preço

Danaher Corp Previsão

Preço-alvo

By TipRanks

28.05% parte superior

Previsão para 12 meses

Média 262.71 USD  28.05%

Máximo 300 USD

Mínimo 240 USD

Com base em 17 analistas de Wall Street que oferecem metas de preço de 12 meses para Danaher Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

17 ratings

13

Comprar

4

Manter

0

Vender

Pontuação Técnica

By Trading Central

199.78 / 210.26Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Weak Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

106 / 386 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.